The company's cumulative investment attraction, which aims to develop innovative bio-new drugs for cancer and incurable diseases, amounts to 60.9 billion. The reason why investors value Rznomics highly is the "Trans-Splicing Ribozyme" platform technology. This technology removes the bad-tempered RNA sequence that causes incurable diseases in the body and injects enzymes (ribozyme) into the area so that good-tempered RNA can be produced. Professor Lee has been studying a technology that induces the activity of therapeutic genes in cells by editing targeted RNA, which is a treatment target, into therapeutic RNA for 20 years. In particular, through research to increase the safety of enzymes, enzymes with therapeutic functions were developed for the first time in vivo.
Rznomics is challenging the development of liver cancer treatments using this technology. Following the announcement of the results of research on liver cancer cell death using the RNA substitution enzyme platform in the official journal of the U.S. Genetic Cell Therapy Association, the domestic Ministry of Food and Drug Safety and the U.S. Food and Drug Administration approved phase 1 and 2a clinical trials for "RZ-001", a candidate for liver cancer treatment.
It is also studying glioblastoma of malignant brain tumors and a treatment for hereditary retinal pigmentation. And It is also considering the possibility of developing treatments for neurological and cognitive diseases such as Alzheimer's and Ret syndrome.
Professor Lee had been considering starting a business early on thanks to his advisor's teaching at the time of his Ph.D. ‘s saying that "he should not be satisfied with leaving research results and names on a few pages of paper."
"I believe that the technology developed through sweat with researchers with the support of taxpayers' money should not be replaced," he said. "Our goal is to grow into a global company based on unique platform technology and pipelines that prove the value of this technology."